drugset / Trial / NCT06169085

Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants

NCT06169085

Phase 1 Completed 32 enrolled Guangdong Raynovent Biotech Co., Ltd
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the safety, tolerability and PK of Leritrelvir in elder participants

Timeline

Start
2023-08-24
Primary completion
2023-09-20
Completion
2023-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Leritrelvir Unknown 400 mg Oral

Indications

No indication recorded.